Outstanding support in first-hand drug development and registration
Although we are a mid-sized CRO, we have often worked with first-in-class drug products that usually consist of new, very challenging professional issues and a network of complex and interconnected pathways from both scientific and regulatory point of view. Usually this continuous work on finding new ways and solving the unexpected problems are the most significant cost generators in a study.
Over the past two decades, we have experienced that innovative drug development requires a special mixture of expertise, creativity and significantly different approach from the usual clinical development routines.



